Jiang X W, Liang Z K, Zeng L, Yuan Y L
Research Center of Medical and Pharmaceutical Bioengineering, Ministry of Health, National and Regional Joint Engineering Laboratory for Clinical Medical Molecular Diagnostics, Guangzhou 510665, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Jul 6;57(7):1124-1130. doi: 10.3760/cma.j.cn112150-20220824-00836.
The application of metagenomic second-generation sequencing (mNGS) is shifting from research to clinical laboratories due to rapid technological advances and significant cost reductions. Although many studies and case reports have confirmed that the success of mNGS in improving the prevention, diagnosis, treatment and tracking of infectious diseases, there are still some obstacles that must be overcome. The results of mNGS show all the possible pathogens in the sample, however, in the face of thousands of microbes that can infect humans, it remains challenging to accurately identify the key pathogens. So far, there is no unified interpretation standard for mNGS in clinical practice. This article reviews the interpretation of mNGS results for pathogen infection in different systems, the clinical interpretation and application regulations of mNGS results, and the challenges of mNGS interpretation in pathogen diagnosis.
由于技术的快速进步和成本的大幅降低,宏基因组二代测序(mNGS)的应用正在从研究实验室转向临床实验室。尽管许多研究和病例报告已经证实mNGS在改善传染病的预防、诊断、治疗和追踪方面取得了成功,但仍有一些障碍必须克服。mNGS的结果显示了样本中所有可能的病原体,然而,面对数千种可感染人类的微生物,准确识别关键病原体仍然具有挑战性。到目前为止,临床实践中尚无mNGS的统一解读标准。本文综述了不同系统中mNGS结果对病原体感染的解读、mNGS结果的临床解读及应用规范,以及mNGS在病原体诊断解读方面的挑战。